Skip to main content

MDS Revenues Surge on Mass Spec Sales

NEW YORK, Sept. 9 (GenomeWeb News) - Buoyed by sales of its 4000 series of mass spec instruments, Toronto-based MDS today reported a 5 percent growth in earnings for its third quarter ending July 31.

 

The company, which is undergoing a strategic reorganization, had revenues of CA$465 million, up from CA$444 million for the year-ago quarter as sales for the company's API 4000 and 4000 Qtrap mass spec instruments increased 36 percent, the company said. Net income was CA$50 million, compared to CA$33 million for the same quarter in 2003.

 

MDS has net revenues of and finished the quarter with CA$273 million in cash and cash equivalents. The company reported a loss of CA$7 million on research and development, compared to CA$11 million in Q3 '03.

 

On Sept. 1, MDS and Applied Biosystems announced an expansion of their mass spectrometry joint venture (click here to read the article).

 

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.